Home

kort Woods Premonition sage 217 breakthrough Hurtig Statistikker Sprængstoffer

Sage Therapeutics surges 70% after depression drug breakthrough
Sage Therapeutics surges 70% after depression drug breakthrough

Small Clinical Trials Lead To Big Results
Small Clinical Trials Lead To Big Results

Sage advice: psychiatric drug development is tough | Evaluate
Sage advice: psychiatric drug development is tough | Evaluate

Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch

Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram

Jorge Luna on LinkedIn: So proud of my amazing team who won the Sage Therapeutics 2019 Field… | 59 comments
Jorge Luna on LinkedIn: So proud of my amazing team who won the Sage Therapeutics 2019 Field… | 59 comments

Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd

Rx Product News: April 2023
Rx Product News: April 2023

Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha

Biogen signs deal with Sage to develop depression, tremor therapies
Biogen signs deal with Sage to develop depression, tremor therapies

FDA Provides Expedited Path Forward For Sage's Depression Treatment SAGE-217 | BioSpace
FDA Provides Expedited Path Forward For Sage's Depression Treatment SAGE-217 | BioSpace

sage-10k_20181231.htm
sage-10k_20181231.htm

Bipolar Depression: How do we treat it?
Bipolar Depression: How do we treat it?

Sage Therapeutics Could Be In For A Depressing FDA Review (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Could Be In For A Depressing FDA Review (NASDAQ:SAGE) | Seeking Alpha

Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha

Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert

Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha

Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News

Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics' SAGE-217 fails in late-stage depression trial

Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage surges after depression drug gets rapid path to approval - PMLiVE

Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston

Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics and Biogen pursue FDA approval for zuranolone

Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire

Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days